MX2021004273A - Proteinas de citomegalovirus modificadas y complejos estabilizados. - Google Patents

Proteinas de citomegalovirus modificadas y complejos estabilizados.

Info

Publication number
MX2021004273A
MX2021004273A MX2021004273A MX2021004273A MX2021004273A MX 2021004273 A MX2021004273 A MX 2021004273A MX 2021004273 A MX2021004273 A MX 2021004273A MX 2021004273 A MX2021004273 A MX 2021004273A MX 2021004273 A MX2021004273 A MX 2021004273A
Authority
MX
Mexico
Prior art keywords
hcmv
complexes
stabilized complexes
modified cytomegalovirus
modified
Prior art date
Application number
MX2021004273A
Other languages
English (en)
Inventor
Enrico Malito
Sumana Chandramouli
Andrea Carfi
Matthew James Bottomley
Kate Luisi
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2021004273A publication Critical patent/MX2021004273A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/04—Varicella-zoster virus
    • C07K14/045—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen polipéptidos del complejo pentámero de citomegalovirus humano mutante (HCMV), métodos para prepararlos y su uso en complejos y composiciones de proteínas de HCMV. En particular, se describe el uso de polipéptidos de HCMV modificados para estabilizar complejos de HCMV o desenmascarar un epítopo de pentámero.
MX2021004273A 2018-10-17 2019-10-15 Proteinas de citomegalovirus modificadas y complejos estabilizados. MX2021004273A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862746804P 2018-10-17 2018-10-17
PCT/IB2019/058777 WO2020079586A1 (en) 2018-10-17 2019-10-15 Modified cytomegalovirus proteins and stabilized complexes

Publications (1)

Publication Number Publication Date
MX2021004273A true MX2021004273A (es) 2021-12-10

Family

ID=68296588

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004273A MX2021004273A (es) 2018-10-17 2019-10-15 Proteinas de citomegalovirus modificadas y complejos estabilizados.

Country Status (8)

Country Link
US (1) US11932669B2 (es)
EP (1) EP3866845A1 (es)
JP (1) JP2022505094A (es)
CN (1) CN113271968B (es)
BR (1) BR112021006812A2 (es)
CA (1) CA3116175A1 (es)
MX (1) MX2021004273A (es)
WO (1) WO2020079586A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021245611A1 (en) 2020-06-05 2021-12-09 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
CA3202549A1 (en) 2020-12-02 2022-06-09 Glaxosmithkline Biologicals Sa Novel antigens
WO2023223255A1 (en) * 2022-05-20 2023-11-23 Glaxosmithkline Biologicals Sa Modified varicella zoster virus glycoprotein e proteins

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920701453A (ko) 1989-03-17 1992-08-11 미리엄 디. 멕코나헤이 유전자발현의 외부조절
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
AU782123B2 (en) * 1999-06-25 2005-07-07 Aaron Diamond Aids Research Center, The Stabilized viral envelope proteins and uses thereof
EP3031469B1 (en) 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
BRPI0916443A2 (pt) 2008-07-16 2017-10-31 Inst Res Biomedicine anticorpos de neutralização de citomegalovírus humanos e uso dos mesmos
EP2320945A4 (en) 2008-07-30 2013-02-27 Emergent Biosolutions Inc STABLE VACCINE FORMULATIONS AGAINST ANTHRAX
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
CA2878344A1 (en) 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins
EP3269388A1 (en) 2012-10-30 2018-01-17 Pfizer Inc. Recombinant particle based vaccines against human cytomegalovirus infection
WO2015082570A1 (en) * 2013-12-03 2015-06-11 Hookipa Biotech Ag Cmv vaccines
PE20170301A1 (es) 2014-05-08 2017-03-30 Pfizer Medios y metodos para el tratamiento cmv
BE1023213B1 (fr) * 2014-05-27 2016-12-21 Glaxosmithkline Biologicals Sa Complexes issus du cytomegalovirus et leurs utilisations
EP3048114A1 (en) * 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
CA3002922A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
US11833198B2 (en) * 2017-03-28 2023-12-05 Children's Hospital Medical Center Norovirus S particle based vaccines and methods of making and using same

Also Published As

Publication number Publication date
JP2022505094A (ja) 2022-01-14
BR112021006812A2 (pt) 2021-07-20
CN113271968A (zh) 2021-08-17
US20210277067A1 (en) 2021-09-09
WO2020079586A9 (en) 2021-05-06
CN113271968B (zh) 2024-06-14
US11932669B2 (en) 2024-03-19
WO2020079586A1 (en) 2020-04-23
CA3116175A1 (en) 2020-04-23
EP3866845A1 (en) 2021-08-25

Similar Documents

Publication Publication Date Title
MX2021004273A (es) Proteinas de citomegalovirus modificadas y complejos estabilizados.
MX2020011257A (es) Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos.
PH12019502621A1 (en) Antibody-cytokine engrafted proteins and methods of use in the treatement of cancer
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
EP4248996A3 (en) Anti-trem2 antibodies and methods of use thereof
MX2020010075A (es) Constructos de polipeptido de lisina-peptido anti-microbiano (amp), lisinas, polinucleotidos aislados que codifican para estas, y sus usos.
MX2021003475A (es) Metodos de purificacion de proteinas.
EP3946408A4 (en) CHEMICAL PROTEINS AND CHEMICAL PROTEIN COMPLEXES AGAINST FMS-LIKE TYROSINE KINASE 3 (FLT3)
MY193353A (en) Anti-vegf protein compositions and methods for producing the same
MX2019012525A (es) Proteinas de citomegalovirus modificadas y complejos estabilizados.
MX2022005547A (es) Derivados terapeuticos de interleucina-22.
IL277790A (en) Human neuregulin-1 recombinant chimeric protein preparations and methods of using them
WO2021181233A3 (en) Cd80-fc fusion protein and uses thereof
EP4013791A4 (en) ANTIBODIES BINDING TO LRP5 PROTEINS AND METHODS OF USE
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
MX2021006922A (es) Constructo multigenico para la expresión de proteínas inmunoduladoras y métodos de uso.
BR112019020386A2 (pt) vacinas de peptídeos de pd-1 humana e usos das mesmas
EA202190249A1 (ru) Пептидные соединения и их терапевтическое применение
MX2019011419A (es) Proteinas hidrolizadas de hortalizas adaptadas para el empleo en la alimentacion de bebes.
EA202191756A1 (ru) Гетеродимерные белки для модулирования т-клеток типа гамма/дельта
MX2021006589A (es) Uso de un complejo de proteinas il-15 junto con un anticuerpo contra pd-l1 para el tratamiento de enfermedades tumorales.
EA201991340A1 (ru) Способы индуцирования иммунологической толерантности к факторам свертывания крови